Curriculum Vitae

Giovannino Silvestri, Biologist, Ph.D.
Marlene & Stewart Greenebaum Comprehensive Cancer Center,
University of Maryland School of Medicine

Date March 25, 2024

Contact Information

Business Address: Greenebaum Comprehensive Cancer Center
655 West Baltimore Street, 9-020
Baltimore, 21201
Phone Number: 4435297878
Email: Gsilvestri@som.umaryland.edu
Foreign Languages: English (Fluently), Italian (Native Language)
Web page: http://www.medschool.umaryland.edu/profiles/Silvestri-Giovannino/

Education

2003-2006 B.S., Biology, University of Calabria, Italy.
2006-2009 M.S., Biology, University of Calabria, Italy (Magna cum Laude).
2010-2013 Ph.D., Cellular and Molecular Pathology and Biology, University of Verona, Italy
Thesis Advisor – Dr. Claudio Sorio.
"Biochemical and functional characterization of the oncosuppressor gene Protein Tyrosine Phosphatase Receptor Gamma".

Dr. **Giovannino Silvestri** received his M.S. in Pathology and Molecular Biology (Summa cum laude) from the University of Calabria in 2009, Italy. In 2013, he earned his Ph.D. in Molecular and Cellular Biology and Pathology from the University of Verona, Italy, working in Dr. Sorio's laboratory on assessing the role of the Protein Tyrosine Phosphatase Receptor Gamma (PTPRG) in Chronic Myelogenous Leukemia (CML). Dr. Silvestri's research has been dealing with malignant hematology since 2009. His interest has been focused for the past ten years on understanding the molecular mechanisms responsible for the emergence, maintenance and progression of leukemias in particular on CML. In 2013, he joined Prof. Perrotti's laboratory at University of Maryland Baltimore (UMB), Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore MD, USA where he is studying the role of miRNAs in the cross-talk between leukemic stem, stromal and immune cells. Dr. Silvestri has broad background in the molecular biology of cancer with specific training in chronic myelogenous leukemia (CML) research. During the few years spent in the USA, he focused his efforts in identifying novel mechanisms of stemness in CML. Dr. Silvestri's research interest is on the role of non-coding RNAs as regulators of normal and leukemic stem and progenitor cell function and to develop new therapeutic drugs that will improve outcome of CML patients resistant to tyrosine kinase inhibitor-based therapies and eradicate the disease at stem cell level. In Dr. Rathinam Lab at

The Institute of Human Virology, he engaged in the identification of signal transduction pathways that contribute to the transformation of Normal Hematapoietic Stem Cells into Leukemia Stem Cells. In addition, he focused on the importance of post-translational modifications of signal transducers in the phenomenon of Leukemic transformation using mouse models. Dr. Silvestri is currently working on the Veterans Affairs Review Merit Grant awarded to Dr. Baer (Professor of Medicine and Director, Hematologic Malignancies and Co-Leader, Experimental Therapeutics Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center) entitled " Enhancing FLT3Inhibitor efficacy in Acute Myeloid Leukemia with FLT3-ITD".

Post Graduate Education and Training

2005-2006 Internship in Anatomy Pathology, Centro Sanitario, University of Calabria, Italy.
2008-2009 M.S. student, Biology, University of Calabria, Italy
2010-2013 Ph.D. student, Mol. and Cellular Bio. and Pathol., University of Verona, Italy.
2013-2018 Post-Doctoral Fellow, Mol. Oncology, University of Maryland Baltimore, USA.
2018-2018 Research Associate, Program in Oncology, University of Maryland Baltimore, USA.
2019-2023 Research Associate, IHV, University of Maryland Baltimore, USA.
2023-pres. Research Associate, Greenebaum CCC, University of Maryland Baltimore, USA.

Academic Appointments

2013-2018 Post-Doctoral Fellow, Mol. Oncology, University of Maryland Baltimore, USA.
2018-2018 Research Associate, Program in Oncology, University of Maryland Baltimore, USA.
2019-2023 Research Associate, IHV, University of Maryland Baltimore, USA.
2023-pres. Research Associate, Greenebaum CCC, University of Maryland Baltimore, USA.

Professional Society Membership

2015-present Member, American Society of Hematology (ASH).
2015-present Member, American Association for the Advancement of Science (AAAS).
2016-present Member, The International CML Foundation (iCMLf)
2017-present Associate Member, American Association for Cancer Research (AACR).

Honors and Awards

2009, Best Graduate Award 2009, University of Calabria, Italy, awarded for distinguished performance in biology.
2010-13, Ph.D. Student Fellowship, Italian Ministry of Health, University of Verona, Italy.
2012, 14th ESH-iCMLf Travel Award, Baltimore, USA.
2014, 16th ESH-iCMLf Travel Award, Philadelphia, USA.
2015, Award for Best poster presentation, University of Maryland, USA.
2015, American Society of Hematology Abstract Award winner, Orlando, USA.
2017, September Postdoc Appreciation Month, University of Maryland, USA

2018, Member Memory Board and Membership Testimonial, Selected from The American Association for Cancer Research (AACR), Chicago, USA.
2022, Silver Plaque Award given by the Mayor of Rende for scientific research career, Italy.

Professional Activities

2012, MicroFTIR stage and performing experiments at the Synchrotron Soleil, Paris, France.
2013, Organized laboratory planning and maintenance, University of Maryland, USA.
2015, Mentor laboratory for *The Nathan Schnaper Summer Intern Program (NSIP) in cancer Research* at Universityof MarylandBaltimore Greenebaum CCC, Baltimore, USA
2018-present, Postdoc Peer Mentor Program, University of Maryland, USA.
2018-present Judge, *Undergraduate Poster Competition 2018,* Stevenson University and Johns Hopkins Medical Institution, Baltimore, USA.Selected by the Collaborative Teaching Fellows Program to evaluate research posters of undergraduate students and excite them about research careers.
2019, Judge, 42nd Medical Research Day (MSRD), University of Maryland, USA.
2020, Judge, 43nd Medical Research Day (MSRD), University of Maryland, USA.
2021, Judge, 44nd Medical Research Day (MSRD), University of Maryland, USA.
2022, Judge, 45nd Medical Research Day (MSRD), University of Maryland, USA.
2023, Judge, 46nd Medical Research Day (MSRD), University of Maryland, USA.

Local and National Service

Editorial Board

- Review Editor on the Editorial Board of Molecular and Cellular Oncology (specialty section of Frontiers in Oncology and Frontiers in Cell and Developmental Biology).
  https://loop.frontiersin.org/people/374295/overview

- Review Editor on the Editorial Board of MDPI Journals.
  https://www.mdpi.com/journal/jcm/submission_reviewers

Peer review activities for international journals

- Genes
- Cancers
- Journal of Clinical Medicine
- Journal of Cellular Physiology
- Oncotarget
- Frontiers in Oncology
- Healthcare
- Frontiers in Cell and Developmental Biology
- Vaccines
- Pharmaceuticals
- Blood
- International journal of cancer
- Cellular Signaling

- BioMed Research International
- Journal of Blood Medicine
- BioEssays
- Pathogens

Local Service

2018-present Postdoc Peer Mentor Program, University of Maryland, USA.

International Service

Grant Reviewer:
2021, Health Research Council of New Zealand (HRC)

Teaching Service

Undergraduate Student Teaching

2015 Mentor laboratory for *The Nathan Schnaper Summer Intern Program (NSIP) in cancer Research* at University of Maryland Baltimore Greenebaum CCC, Baltimore, USA.
2017 Mentor laboratory for *The Nathan Schnaper Summer Intern Program (NSIP) in cancer Research* at University of Maryland Baltimore Greenebaum CCC, Baltimore, USA.

Grants and contract

Grant Reviewer:

2021, Health Research Council of New Zealand (HRC)

Ongoing Research Support:

Veterans Affairs AI01BX005120-01A2 07/06/2021-06/31/2025

PI: Baer

Role: Key personnel

Title: Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD.

Acute myeloid leukemia (AML) accounts for 80% of adult acute leukemia and has a five-year survival rate of only 25%. It is more common in men and incidence increases with age. AML is associated with military service in specific groups of Veterans. It also develops following treatment for other cancers, including those common in Veterans. This merit award proposal explores approaches to improving treatment for AML with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), a molecular abnormality present in AML cells in 30% of patients and associated with poor treatment outcomes. The work has the potential to improve outcomes in Veterans who develop this common and unfavorable AML subtype, including following military and medical exposures. The long-term goal is to develop clinical trials of multi-targeting approaches to improving outcomes of patients with AML with FLT3-ITD

NIH/NIAID 1R21AI174952-01 02/06/2022-01/31/2025

PI: Rathinam

Role: Key personnel

Title: Decoding HIV-1 mediated Hematopathology.

Human Immunodeficiency Virus (HIV)-1 infection causes severe hematopathology; including anemia, neutropenia, thrombocytopenia, leukemia, lymphoma, inflammatory disorders, and bone marrow failure. A deeper understanding of the cellular and molecular mechanisms that regulate hematopoietic stem cells (HSCs) in the BM of patients with HIV-1 infection would be valuable in designing novel therapies for HIV-associated hematological diseases.

Completed/Ended Research Support:

NIH/NHLBI 1R01HL132194 02/15/2017-01/31/2023

PI: Rathinam

Role: Key personnel

Title: NF-KB signaling in the control of Hematopoiesis. The goal of this project is to assess the precise role of NF-KB in hematopoietic stem cells that would be essential to understand and treat hematopoietic diseases that arise due to defective NF-KB activation.

NIH/NCI R01CA163800 01/31/2012-01/31/2019

PI: Perrotti

Role: Key personnel

Title: Role of microRNAs in the regulation of CML stem cell survival and self-renewal.

The goal of this project is to assess the role of microRNAs targeting in a canonical or decoy manner the BCR- ABL1/Jak2/SET-PP2A/b-catenin pathway in survival/self-renewal of leukemic stem and progenitor cells.

NIH-NCI 1R21CA209183-01 07/13/2016-06/30/2019

PI: Perrotti

Role: Key Personnel

Title: Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia.The goal of this project is to assess the role of SETBP1 and that of the PP2A inhibitory complex in the survival and self-renewal of Ph+ B-ALL stem cells.

Ph.D. Student Fellowship, Italian Ministry of Health, University of Verona,Italy 01/01/2010-05/30/2013

PI: Silvestri

Publications

Peer-reviewed journal articles

1. Bellisola G., Cinque G., Vezzalini M., Moratti E., **Silvestri G**., Redealli S., Gambacorti Passerini C., Wehbe K., and C. Sorio. Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis, ***Analyst***, 138:3934-3945, 2013.
2. Bellisola G, Bolomini Vittori M, Cinque G, Dumas P, Fiorini Z, Laudanna C, Mirenda M, Sandt C, **Silvestri G**, Tomasello L, Vezzalini M, Wehbe K, Sorio C. Unsupervised explorative data analysis of normal human leukocytes and BCR/ABL positive leukemic cells mid-infrared spectra. ***Analyst***, 140:4407-22, 2015.
3. Perrotti D, **Silvestri G**, Stramucci L. Chronic Myelogenous Leukemia (CML): Current Research Focus. ***Haematologica,*** 9:91-102, 2015.
4. Laidlaw K., Berhan S., Liu S, **Silvestri G**, Holyoake T, Frank D, Aggarwal B.B., Perrotti D**.**, Jørgensen H., Arbiser J. Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. ***Oncotarget***, 7:51651 doi: 10.18632/oncotarget.10541, 2016.

5. Perrotti D, **Silvestri G**, Stramucci L, Yu J, Trotta R. Cellular and Molecular Networks in Chronic Myeloid Leukemia: the leukemic stem, progenitor and stromal cell interplay. ***Current drug targets***, 18:377-388, 2017
6. Srutova K, Curik N, Burda P, Savvulidi F, **Silvestri G**, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D and Machova Polakova K. BCR-ABL1 mediated miR-150 downregulation throught MYC contributed to myeloid differentiation block and resistance in chronic myeloid leukemia. ***Haematologica***, 103(12):2016-2025. doi: 10.3324/haematol.2018.193086, 2018.
7. **G Silvestri**, R Trotta, L Stramucci, JJ Ellis, JG Harb et al. Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions, ***Blood Cancer Discovery,*** 1:1. doi:10.1158/0008-5472. BCD-19-0039*,* 2020.
8. *Palma G, *Pasqua T, **Silvestri G**, Rocca C, Gualtieri P, Barbieri A, De Bartolo A, De Lorenzo A, Angelone T, Avolio E and Botti G. PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19, ***Frontiers in Immunology***, 11:2094. doi: 10.3389/fimmu.2020.0209, 2020. *equally contributed.
9. Benedetti*, F.; **Silvestri*, G**.; Nartuhi*, C.M.; Weichseldorfer, M.; Munawwar, A.; Cash, M.N.; Dulcey, M.; Vittor, A.Y.; Ciccozzi, M.; Salemi, M.; Latinovic, O.S.; Zella D. ; Comperison of SARS-CoV-2 receptors expression in primary endothelial cells and retinoic acid-differentiated human neuronal cells. ***Viruses***, 13(11):2193 doi: 10.3390/v13112193, 2022 *equally contributed.
10. Benedetti F.*; **Silvestri G**.*; Saadat S.; Denaro F.; Latinovic S.O.; Davis H.; Williams S.; Bryant L. J.; Ippodrino R.; Rathinam V. C.; Gallo C. R.; Zella D.; Mycoplasma DNAK increases DNA copy Number Variants *in vivo*. ***The Proceedings of the National Academy of Sciences (PNAS)***, 120 (30) e2219897120, 2023 *equally contributed.
11. Jonelle K. Lee, Aditi Chatterjee, Mario Scarpa, Christopher M. Bailey, Sandrine Niyongere, Prerna Singh, Moaath K. Mustafa Ali, Shivani Kapoor, Yin Wang, **Giovannino Silvestri*** and Maria R. Baer*; Pim kinase inhibitors increase gilteritinib cytotoxicity in FLT3-ITD acute myeloid leukemia through GSK-3β activation and c-Myc and Mcl-1 proteasomal degradation. ***Cancer Research Communications,*** 4(2):431-445, 2024.
12. Francesca Benedetti[#], **Giovannino Silvestri**[#], Frank Denaro, Giovanni Finesso, Rafael Contreras-Galindo, Arshi Munawwar, Sumiko Williams, Harry Davis, Joseph Bryant, Yin Wang, Enrico Radaelli, Chozha V. Rathinam, Robert C. Gallo* and Davide Zella*; Mycoplasma DnaK Expression Increases Cancer Development In Vivo Upon DNA Damage. ***The Proceedings of the National Academy of Sciences (PNAS)***, 121 (10) e2320859121, 2024. # Equally contributed.
13. Benedetti F.; Mongodin F. E.; Badger H. J.; Munawwar A.; Cellini A.; Yuan W.; **Silvestri G**.; Kraus N. C.; Marini S.; Salemi M.; Tettelin H.; Gallo C. R.; Zella D.; Bacterial DnaK Reduces the Activity of Anti-cancer Drugs Cisplatin and 5FU. ***Journal of Translational Medicine*** 22, 269, 2024.
14. Basta D, Latinovic OS, **Silvestri G***. Potential Advantages of a Well-balanced Nutrition Regimen for People Living with Human Immunodeficiency Virus Type -1. ***J AIDS HIV Treat.*** 6(1):11-27, 2024.

Submitted or In-Revision Peer-reviewed journal articles

1. **Giovannino Silvestri** and Chozha Vendan Rathinam; Trim28 plays an indispensable role in maintaining functions and transcriptional integrity of hematopoietic stem cells. ***Stem Cells***, 2023, Under Review.

Major Invited Speeches

National

1. **Silvestri, G.,** MicroRNAs as regulators of stem and progenitor CML cells function, ESH-iCMLf, Philadelphia, 2014.
2. **Silvestri, G.,** Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML, 57th ASH, Orlando, 2015.

International

1. **Silvestri, G.,** The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. ESH-iCMLf, Estoril, Portugal, 2017.

Proffered Communications: oral (O) and poster (P) poster presentation

1. Morsi H., El Ayoubi H., Moratti E., Vezzalini M., **Silvestri G.**, Stradoni R., Murineddu M., Gabbas A., Monne M. and C. Sorio. High Resistance Rate of Chronic Myeloid Leukaemia (CML) to Imatinib Myselate (IM) Might be related to Protein Tyrosine Phosphatase Receptor Type Gamma (PTPRG) Down-Regulation. *Proceedings Qatar Foundation* Annual Research Forum *Epub: November 2011* (O).
2. Bellisola G., Cinque G., Vezzalini M., **Silvestri G.**, Redaelli S., Gambacorti Passerini C., Wehbe K. and C. Sorio. Rapid identification of drug-resistance/sensitivity in leukemic cells by Fourier Transform InfraRed microspectroscopy (microFTIR) and unsupervised Hierarchical Cluster Analysis (HCA) *Proceeding of the Synchrotron Radiation User Meeting* Oxford, UK, September 2012. (P).
3. **Silvestri G*.**, Mirenda M., Vezzalini M., Moratti E., Laudanna C. and C. Sorio. Molecular mechanisms of the antiproliferative effect of Protein Tyrosine Phosphatase Receptor-like Gamma (PTPRG): BCR/ABL and LYN kinase as key targets. *Proceeding of the 14th ESH-iCMLf International Conference on CML Biology and Therapy*. Baltimore, Usa, September 2012 (P) (*): recipient of the iCMLF travel award.

4. Bellisola G., Cinque G., Vezzalini M., Moratti E., **Silvestri G.**, Redaelli S., Wehbe K. and C. Sorio. Rapid identification of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy (microFTIR) and unsupervised pattern recognition. *Proceeding of the 14th ESH-iCMLf International Conference on CML Biology and Therapy*. Baltimore, USA, September 2012 (P).
5. Bellisola G., Cinque G., Sandt C., Dumas P., **Silvestri G.** and C. Sorio. Oncosuppressive effect of direct transduction of receptor-type tyrosine-protein phosphatase gamma (PTPRG) intracellular catalytic domains in K562 cells. *Proceeding of the 15th ESH-iCMLf International Conference on CML Biology and Therapy*. Estoril, Portugal, September 2013 (P).
6. Tomasello L., **Silvestri G.**, Della Peruta M., Fiorini Z., Vezzalini M. and Claudio Sorio. Protein Tyrosine Phosphatase Receptor Type Gamma is an inhibitor of critical BCR/ABL driven pathways in Chronic Myeloid Leukemia. *Societa' Italiana di Cancerologia.* Ferrara, Italy, September 2014 (O).
7. Bellisola G., Tomasello L., Fiorini Z., **Silvestri G.**, Vezzalini M. and Claudio Sorio. Direct transduction of Receptor-Type Protein Tyrosine-Phosphatase Gamma (PTPRG) intracellular catalytic domains in K562 cells. *Societa' Italiana di Cancerologia.* Ferrara, Italy, September 2014 (P).
8. **Silvestri G*.**, Ellis J., Stramucci L., Harb J.G., Neviani P., Marcucci G., Reid A., Milojkovic D., Apperley J., Baer M., Trotta R., and D. Perrotti. MicroRNAs as regulators of stem and progenitor CML cells function. Peer reviewed and printed in the Proceedings of the 2014 ESH-iCMLf International Conference on CML-Biology and Therapy, Philadelphia (O). (*): Invited Speaker.
9. **Silvestri G.,** Ellis J.J., Stramucci L., Harb J.G., Neviani P., Marcucci G., Roy D-C., Hokland P., Milojkovic D., Reid A., Apperley J.F., Livak F.M., Baer M.R., Trotta R., and D. Perrotti. miR-300 acts as a tumor suppressor in Ph^+ progenitors by Modulating the JAK2-SET/PP2A-B catenin interplay. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 56th ASH Annual Meeting 2014 (P).
10. **Silvestri G*.,** Justin Ellis, Lorenzo Stramucci, Jason G Harb, Paolo Neviani, Guido Marcucci, Denis-Claude Roy, Peter Hokland, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M. Livak, Maria R. Baer, Rossana Trotta, and Danilo Perrotti. miR-300 acts as a tumor suppressor in Ph^+ progenitors by Modulating the JAK2-SET/PP2A-B catenin interplay. UMB Cancer Center Retreat, Baltimore, USA, May 18, 2015. (P) (*): Best Poster Presentation.
11. **Silvestri G*.,** Stramucci L, Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger MW., Bhatia R., Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R. and Perrotti D. Role of the MSC-derived exosomal and endogenous JAK2-SET/PP2A-beta-catenin-modulator miR-300 in leukemic stem/progenitor and NK cell proliferation and survival in CML. Peer reviewed and printed in the Proceedings of the 2015 ESH-iCMLf International Conference on CML-Biology and Therapy, Estoril, Portugal (O).
(*): Best scored Biology Abstract.
12. **Silvestri G*.,** Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C, Hokland P., Deininger MW., Bhatia R., Gambacorti-

Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R., and Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 57th ASH Annual Meeting 2015 (O). (*): ASH travel award.

13. Trotta R., **Silvestri G.**, Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger M.W., Bhatia R., Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., and Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Proceeding of the AACR Annual Meeting (New Orleans, LA) 2016 (P).
14. **Silvestri G.**, Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger M.W., Bhatia R., Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R., and Perrotti D. Role of Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Peer Reviewed and Published in the Haematologica (Suppl.) dedicated to the European Hematology Association (EHA) Annual Meeting. Copenhagen, Danmark. 2016. (O).
15. Yu J.E., **Silvestri G**., Stramucci L., Livak F.M., Baer M.R., Trotta R., and Perrotti, D. The Role of SETBP1 in Leukemia-Initiating Cell Survival and Self-Renewal in Adult Ph^+ B-ALL. ESH-iCMLF ESH-iCMLf International Conference on CML-Biology and Therapy, Houston TX Sept. 2016 (O).
16. Yu J.E., **Silvestri G.,** Stramucci L., Sanada M., Yamaguchi T., Du Y., Westermarck J., Caligiuri M.A., Garzon R., Milojkovic D., Apperley J.F., Roy D-C., Marcucci G., Calabretta, B., Baer M.R., Trotta R. and Perrotti D**.** *Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 –Mediated Suppression of PP2A Activity* Peer Reviewed and Published in Blood (Suppl.) dedicated to the 58th ASH Annual Meeting 2016 (P).
17. P. Burda, N. Čuřík, K. Šrůtová, F. Savvulidi, **G. Silvestri**, H. Klamová, P. Pecherková, Ž. Sovová, J. Koblihová, T. Stopka, D. Perrotti, K. Machová Poláková *Myc-dependent repression mechanism of the mir-150 transcriptional regulation in chronic myeloid leukemia*. Peer Reviewed and Published in the Leukemia (Suppl.) dedicated to the European Hematology Association (EHA) Annual Meeting. Madrid, Spain. 2017 (P).
18. **Silvestri G.,** Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. *The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity.* UMB CCC Retreat, September 2017 (P).
19. **Silvestri G*.,** Stramucci L., Ellis J., Yu J., Harb JG, Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., , Apperley J.F., Marcucci

G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. *The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity.* ESH-iCMLf International Conference on CML-Biology and Therapy, Estoril, Portugal Oct. 2017 (O). (*): selected for Key note lecture.

20. **Silvestri G.,** Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. *The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity.* Peer Reviewed and Published in Blood (Suppl.) dedicated to the 59th ASH Annual Meeting 2017 (O).

21. **Silvestri G.,** Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. *The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance.* Proceeding of the AACR Annual Meeting (Chicago, IL) 2018 (P).

22. Trotta R., **Silvestri G.**, Stramucci L., Guimond M., Marcucci G., Fan X., Baer M.R., and D. Perrotti. *Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and anti-tumor activity*. Proceeding of the AACR Annual Meeting (Chicago, IL) 2018 (P).

23. Trotta R., **Silvestri G.**, Stramucci L., Guimond M., Marcucci G., Fan X., Baer M.R., and D. Perrotti. Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and anti-tumor activity. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 81():63, DOI: 10.1097/01.qai.0000558015.84504.53, April 2019. (P)

24. **Silvestri G.** *et al.* The 14q32.31 MIR300 DLK1-DIO3 oncosuppressor induces CML and AML cancer stem cell quiescence and inhibits NK cell Immunity. 21st *ESH-iCMLf International Conference on CML-Biology and Therapy*, Bordeaux, France, September. 2019 (O). (*): selected abstract.

25. **Giovannino Silvestri**, Rossana Trotta, Lorenzo Stramucci, Shuzhen Wang, Ann-Kathrin Eisfeld, Bin Zhang, Klara Srutova, Gabriel Pineda, Catriona Jamieson, Fabio Stagno, Paolo Vigneri, Georgios Nteliopoulos, Martin Guimond, Peter Hokland, Michael W Deininger, Francesco Dazzi, Dragana Milojkovic, Jane Apperley, Guido Marcucci, Xiaoxuan Fan, Maria R Baer, Bruno Calabretta, Danilo Perrotti. A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis by Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity. *Blood, The Journal of the American Society of Hematology. (2019) 134 (Supplement_1): 4141.* (P)

26. Francesca Benedetti*, **Giovannino Silvestri***, Saman Saadat, Frank Denaro, Olga S. Latinovic, Harry Davis, Sumiko Williams, Josph Bryant, Chozha V. Rathinam, Robert C.

Gallo, Davide Zella. Characterization of a Mycoplasma DnaK Transgenic Mouse. *World Microbe Forum,* online worldwide, June 2021. *equally contributed.

Clinical Specialty Details:

Certificate in Clinical Trials Operations by Johns Hopkins University.
Certificate earned November 1, 2023.

1. Design and Conduct of Clinical Trials
   Johns Hopkins University
   Taught by: Janet Holbrook, PhD, MPH, Ann-Margret Ervin, PhD, MPH, Stephan Ehrhardt, MD, MPH & Elizabeth A. Sugar, PhD
   Grade Achieved: 87.79%

2. Clinical Trials Data Management and Quality Assurance
   Johns Hopkins University
   Taught by: Janet Holbrook, PhD, MPH, Ann-Margret Ervin, PhD, MPH & David M. Shade, JD
   Grade Achieved: 86.08%

3. Clinical Trials Management and Advanced Operations
   Johns Hopkins University
   Taught by: Ann-Margret Ervin, PhD, MPH, Anne Shanklin Casper, MA & Sheriza Baksh, PhD
   Grade Achieved: 87.34%

4. Clinical Trials Analysis, Monitoring, and Presentation
   Johns Hopkins University
   Taught by: Janet Holbrook, PhD, MPH, Elizabeth A. Sugar, PhD & David M. Shade, JD
   Grade Achieved: 86.23%